Peptide Research: Tesamorelin – Studies, Research Use, and Scientific Background

What is Tesamorelin?

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of 44 amino acids. It is studied in laboratory settings for its ability to stimulate endogenous growth hormone secretion, regulate lipid metabolism, and influence body composition in preclinical models.
For laboratory research use only. Not for human or veterinary use.

Key Scientific Studies

• Growth Hormone Stimulation: A pivotal study published in New England Journal of Medicine (2010) found that tesamorelin administration significantly increased growth hormone and IGF-1 levels in preclinical and clinical research settings.
  Grinspoon et al., 2010
• Lipid Metabolism and Body Composition: Research has shown tesamorelin’s effectiveness in reducing visceral adiposity and improving lipid profiles in laboratory models of metabolic dysfunction.
  Falutz et al., 2010

Laboratory Research Applications

• Investigation of growth hormone secretion and IGF-1 regulation
• Preclinical models of metabolic disorders and lipodystrophy
• Research on visceral fat reduction and lipid metabolism
• Study of GHRH receptor agonist mechanisms

Mechanism of Action (in Research Context)

Tesamorelin binds to GHRH receptors in the pituitary, stimulating the release of endogenous growth hormone. Laboratory studies also highlight its impact on IGF-1 production and metabolic regulation in preclinical models.

Reference Dosing Schedules from Published Studies

The following dosing protocols have been reported in published laboratory and preclinical studies of Tesamorelin:

• Common Dose Range (animal studies): 100–200 mcg/kg, administered subcutaneously
• Clinical Research Dose: 2 mg once daily by subcutaneous injection (for reference from published human trials)
• Duration: Typically 12–26 weeks, depending on protocol